Skip to main content

The Last of HedgeWorld

Thomson Reuters is putting an end to what until days ago remained of HedgeWorld. Excuse me while I shed an inward tear.

HedgeWorld, founded in 1999, was the first news operation to focus squarely, full time, upon the hedge fund industry. The founders lit this candle soon after the self-destruction of Long-Term Capital Management created a broad public desirous of information on this subject. Better to light that one candle, after all, than to curse the darkness.

I was the first hire of those founders -- they brought me on board in the spring of 2000.

HedgeWorld had a complicated corporate history, but in time it was captured by Reuters, and it was run as a semi-autonomous operation beneath that broad Reuteronian sky.

Then, alas, Reuters merged with Thomson, and the Bigs of the two operations put their pointy heads together and decided where they could make cuts. They closed down HW as a news gathering operation in the fall of 2008. That was the end of my involvement.

TR kept on Chris Clair, though. One of our number, indeed the final managing editor of HW, Clair kept the site going. Why did they want the brand name and a web portal bearing that name, but no news gathering? Well, I suppose it helped direct traffic to other TR territories, and it gave its brand to conferences and events.

But now TR has finally given up the ghost.

The "HedgeWorld" conferences have now been rebranded as "PartnerConnect" conferences.

And Clair has this to say:

 Dear friends of HedgeWorld:

Fifteen years ago, HedgeWorld launched with a mission to provide news, research, data, opinion and analysis for a hedge fund industry that was on the verge of explosive growth. At the time, few other similar ventures existed. With a skeleton staff but a ton of moxie, HedgeWorld set out to cover the world of hedge funds. News reports chronicled the industry's rise from misunderstood niche investment clique to misunderstood $2 trillion market moving force. The business was acquired, expanded, acquired again and downsized.

Today I write to tell you the ride is over. Thomson Reuters has decided to discontinue HedgeWorld as a business unit. The web site will no longer be updated. Yet to be determined is what will become of the Lipper hedge fund database, which traces its roots to the old TASS database. Also unknown as of right now is what happens to the thousands of archived news stories and the subscriber database. The conference business will likely continue - albeit under a different brand - with UCG, the firm that recently purchased HedgeWorld's sister publications: Buyouts, VCJ and peHUB. Keep an eye out for that.

As the last man standing editorially for HedgeWorld, I thank you for reading, e-mailing, contributing, speaking, networking, following, friending and retweeting. It's been a hell of a ride, but eventually all waves must break. Those of you who have known HedgeWorld the longest should remember it in its heyday, as an upstart start-up living billing cycle to billing cycle but shining an unapologetic light into a strange corner of the investment world. It was a business that perfectly embodied the entrepreneurial spirit of the industry it sought to cover.

Too many people to list here made HedgeWorld work. They know who they are, and many of you do, too. How Thomson Reuters ultimately winds up the brand is yet to be seen. In truth I have been told before that HedgeWorld was to close, only to see it continued on a weird life support. This time, though, it really seems to be the end. It is for me, at any rate.


I can't beat that as a curtain line. 


Popular posts from this blog

A Story About Coleridge

This is a quote from a memoir by Dorothy Wordsworth, reflecting on a trip she took with two famous poets, her brother, William Wordsworth, and their similarly gifted companion, Samuel Taylor Coleridge.

We sat upon a bench, placed for the sake of one of these views, whence we looked down upon the waterfall, and over the open country ... A lady and gentleman, more expeditious tourists than ourselves, came to the spot; they left us at the seat, and we found them again at another station above the Falls. Coleridge, who is always good-natured enough to enter into conversation with anybody whom he meets in his way, began to talk with the gentleman, who observed that it was a majestic waterfall. Coleridge was delighted with the accuracy of the epithet, particularly as he had been settling in his own mind the precise meaning of the words grand, majestic, sublime, etc., and had discussed the subject with William at some length the day before. “Yes, sir,” says Coleridge, “it is a majestic wate…

England as a Raft?

In a lecture delivered in 1880, William James asked rhetorically, "Would England ... be the drifting raft she is now in European affairs if a Frederic the Great had inherited her throne instead of a Victoria, and if Messrs Bentham, Mill, Cobden, and Bright had all been born in Prussia?"

Beneath that, in a collection of such lectures later published under James' direction, was placed the footnote, "The reader will remember when this was written."

The suggestion of the bit about Bentham, Mill, etc. is that the utilitarians as a school helped render England ineffective as a European power, a drifting raft.

The footnote was added in 1897. So either James is suggesting that the baleful influence of Bentham, Mill etc wore off in the meantime or that he had over-estimated it.

Let's unpack this a bit.  What was happening in the period before 1880 that made England seem a drifting raft in European affairs, to a friendly though foreign observer (to the older brother…

Cancer Breakthrough

Hopeful news in recent days about an old and dear desideratum: a cure for cancer. Or at least for a cancer, and a nasty one at that.

The news comes about because investors in GlaxoSmithKline are greedy for profits, and has already inspired a bit of deregulation to boot. 

The FDA has paved the road for a speedy review of a new BCMA drug for multiple myeloma, essentially cancer of the bone marrow. This means that the US govt has removed some of the hurdles that would otherwise (by decision of the same govt) face a company trying to proceed with these trials expeditiously. 

This has been done because the Phase I clinical trial results have been very promising. The report I've seen indicates that details of these results will be shared with the world on Dec. 11 at the annual meeting of the American Society of Hematology. 

The European Medicines Agency has also given priority treatment to the drug in question. 

GSK's website identifies the drug at issue as "GSK2857916," althou…